Cited by 152Schizophrenia research and treatmentDiabetes Treatment and ManagementPharmacology and Obesity Treatment

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Treatment with antipsychotics and the risk of diabetes in clinical practice

Open access

Kessing, Lars Vedel, Thomsen, Anders Frøkjær, Mogensen, Ulla Brasch, Andersen, Per Kragh·2010·British Journal of Psychiatry

DOI 10.1192/bjp.bp.109.076935

Open this paper in CoChat — free account Open PDF

Abstract

Background: Treatment with antipsychotics seems to increase the risk of developing diabetes but the association is poorly characterised in clinical practice. Aims: To investigate and characterise the incidence of diabetes for people treated with antipsychotic medication in clinical practice. Method: The study used the linkage of registers of all prescribed antipsychotics, antidiabetics and diagnoses of diabetes in Denmark during a period from 1996 to 2005 and identified all people treated with antipsychotics in Denmark and a random sample of about 30% of the total Danish population. Results: In total, 345 937 patients who purchased antipsychotics and 1 426 488 unexposed individuals were included in the study. Among the total population, 50 379 individuals subsequently developed incident diabetes. Compared with unexposed individuals, treatment with first- (rate ratio, RR = 1.53, 95% CI 1.49–1.56) as well as second-generation (RR = 1.32, 95% CI 1.22–1.42) antipsychotics was associated with increased risk of subsequent incident diabetes. The rate of incident diabetes varied substantially between individual second-generation antipsychotic drugs (olanzapine, risperidone clozapine compared with unexposed individuals: low to moderate rate ratio between 1.17 and 1.57; ziprasidone and sertindol: two or more times increased rate ratio; amisulpride, quetiapine and aripiprazole: no significantly increased rate ratio). For both first- and second-generation antipsychotics, the incidence of diabetes increased with the number of prescriptions. Additionally, the incidence of diabetes increased with the number of combined antipsychotic drugs. Conclusions: In clinical practice, treatment with first- and second-generation antipsychotics is associated with an increased risk of developing incident diabetes with large differences between individual drugs. The risk increases with the duration of treatment and with polypharmacy of antipsychotic drugs.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1192/bjp.bp.109.076935

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
The Danish National Hospital Register. A valuable source of data for modern health sciences.
Andersen, T. F., Madsen, M., Jørgensen, J. O. L., Mellemkjoer, L., & Olsen, J. H. (1999) · PubMed · Cited by 2,026
Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes
Boehm, G., Racoosin, J. A., LAUGHREN, T. P., & Katz, R. G. (2004) · Diabetes Care · doi:10.2337/diacare.27.8.2088-a · Cited by 1,204
The Danish Psychiatric Central Register.
Munk‐Jørgensen, P., & Mortensen, P. B. (1997) · PubMed · Cited by 698
Prevalence and Correlates of Diabetes in National Schizophrenia Samples
Dixon, L. B., Weiden, P. J., Delahanty, J. C., Goldberg, R., Postrado, L. T., Lucksted, A. A., & Lehman, A. F. (2000) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033504 · Cited by 570
The Danish registers of causes of death.
Juel, K., & Helweg‐Larsen, K. (1999) · PubMed · Cited by 410
Diabetes mellitus in schizophrenic patients
Mukherjee, S., Decina, P., Bocola, V., Saraceni, F., & Scapicchio, P. L. (1996) · Comprehensive Psychiatry · doi:10.1016/s0010-440x(96)90054-1 · Cited by 368
Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use
Regenold, W. T. (2002) · Journal of Affective Disorders · doi:10.1016/s0165-0327(01)00456-6 · Cited by 290
First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: Systematic review and meta-analysis
Smith, M. J., Hopkins, D., Peveler, R., Holt, R. I. G., Woodward, M., & Ismail, K. (2008) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.107.037184 · Cited by 274
Differential Effects of Risperidone, Olanzapine, Clozapine, and Conventional Antipsychotics on Type 2 Diabetes
Gianfrancesco, F. D., Grogg, A. L., Mahmoud, R. A., Wang, R., & Nasrallah, H. A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1010 · Cited by 238

Flagged first, then by citations

Show all 26 references

Research works printed but not linked: 6

Kristensen, 2000, Identification of the Type 2 Diabetes Population in a Danish County and Evaluation of the Performed Care in a Five-Year Period
2009, National Diabetes Surveillance System
Malig, 1996, The Civil Registration System in Denmark. Technical Paper No 66
2002, Medicinal Product Statistics
1993, International Statistical Classification of Diseases and Health Related Problems, 10th revision [Danish version]
2003, ATC Index with DDDs

Sorted by citations

Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care
DE HERT, M., CORRELL, C. U., BOBES, J., CETKOVICH‐BAKMAS, M., COHEN, D., ASAI, I., DETRAUX, J., GAUTAM, S., MÖLLER, H., NDETEI, D. M., et al. (2011) · World Psychiatry · doi:10.1002/j.2051-5545.2011.tb00014.x · Cited by 2,488
Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta‐analysis
Vancampfort, D., Stubbs, B., Mitchell, A. J., De Hert, M., Wampers, M., Ward, P. B., Rosenbaum, S., & Correll, C. U. (2015) · World Psychiatry · doi:10.1002/wps.20252 · Cited by 1,271
Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.
De Hert, M., Detraux, J., van Winkel, R., Yu, W., & Correll, C. U. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.156 · Cited by 1,145
Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta‐analysis
Vancampfort, D., Correll, C. U., Galling, B., Probst, M., De Hert, M., Ward, P. B., Rosenbaum, S., Gaughran, F., Lally, J., & Stubbs, B. (2016) · World Psychiatry · doi:10.1002/wps.20309 · Cited by 659
Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology
Barnes, T. R. E., Drake, R., Paton, C., Cooper, S. J., Deakin, J. F. W., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I. R., et al. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 615
Atypical Antipsychotics and Metabolic Syndrome: From Molecular Mechanisms to Clinical Differences
Carli, M., Kolachalam, S., Longoni, B., Pintaudi, A. M., Baldini, M., Aringhieri, S., Fasciani, I., Annibale, P., Maggio, R., & Scarselli, M. (2021) · Pharmaceuticals · doi:10.3390/ph14030238 · Cited by 270
Antipsychotics and the Risk of Type 2 Diabetes Mellitus in Children and Youth
Bobo, W. V., Cooper, W. O., Stein, C. M., Olfson, M., Graham, D. J., Daugherty, J. R., Fuchs, D. C., & Ray, W. A. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.2053 · Cited by 229
Type 2 Diabetes Mellitus in Youth Exposed to Antipsychotics
Galling, B., Roldán, A., Nielsen, R. E., Nielsen, J., Gerhard, T., Carbon, M., Stubbs, B., Vancampfort, D., Binder, M. D., Olfson, M., et al. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.2923 · Cited by 229
Safety and tolerability of antipsychotic polypharmacy
Gallego, J. A., Nielsen, J., Binder, M. D., Kane, J. M., & Correll, C. U. (2012) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2012.683523 · Cited by 207
Off-Label Prescribing of Antipsychotics in Adults, Children and Elderly Individuals: A Systematic Review of Recent Prescription Trends
Carton, L., Cottencin, O., Lapeyre‐Mestre, M., Geoffroy, P. A., Favre, J., Simon, N., Bordet, R., & Rolland, B. (2015) · Current Pharmaceutical Design · doi:10.2174/1381612821666150619092903 · Cited by 208
Causes of decreased life expectancy over the life span in bipolar disorder
Kessing, L. V., Vradi, E., McIntyre, R. S., & Andersen, P. K. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.03.027 · Cited by 209
Self-citation
Second-Generation Antipsychotics and Metabolic Side Effects: A Systematic Review of Population-Based Studies
Hirsch, L., Yang, J. J., Bresee, L. C., Jetté, N., Patten, S. B., & Pringsheim, T. M. (2017) · Drug Safety · doi:10.1007/s40264-017-0543-0 · Cited by 182
Insulin action in the brain: cell types, circuits, and diseases
Chen, W., Cai, W., Hoover, B., & Kahn, C. R. (2022) · Trends in Neurosciences · doi:10.1016/j.tins.2022.03.001 · Cited by 184
Association between antipsychotic medication use and diabetes
Holt, R. I. G. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1220-8 · Cited by 162
Effects of Antipsychotic Medications on Appetite, Weight, and Insulin Resistance
Deng, C. (2013) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.05.006 · Cited by 156
Endogenous and Antipsychotic-Related Risks for Diabetes Mellitus in Young People With Schizophrenia: A Danish Population-Based Cohort Study
Rajkumar, A. P., Horsdal, H. T., Wimberley, T., Cohen, D., Mors, O., Børglum, A. D., & Gasse, C. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16040442 · Cited by 137
Course of weight gain and metabolic abnormalities in first treated episode of psychosis: the first year is a critical period for development of cardiovascular risk factors
Pérez‐Iglesias, R., Martínez‐García, O., Pardo‐García, G., Amado, J., García‐Unzueta, M. T., Tabarés‐Seisdedos, R., & Crespo‐Facorro, B. (2013) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713001053 · Cited by 139
Risk of myocardial infarction and stroke in bipolar disorder: a systematic review and exploratory meta‐analysis
Prieto, M. L., Barboza, A. B. C., Bobo, W. V., Roger, V. L., Bellivier, F., Leboyer, M., West, C. P., & Frye, M. A. (2014) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12293 · Cited by 103
Treatment of Peripartum Bipolar Disorder
Clark, C. T., & Wisner, K. L. (2018) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/j.ogc.2018.05.002 · Cited by 98
Antipsychotic polypharmacy: A survey study of prescriber attitudes, knowledge and behavior
Correll, C. U., Shaikh, L., Gallego, J. A., Nachbar, J., Olshanskiy, V., Kishimoto, T., & Kane, J. M. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.02.016 · Cited by 95
Barriers to Self-management of Serious Mental Illness and Diabetes
Blixen, C. E., Kanuch, S., Perzynski, A. T., Thomas, C., Dawson, N. V., & Sajatovic, M. (2016) · American Journal of Health Behavior · doi:10.5993/ajhb.40.2.4 · Cited by 90
Antipsychotic polypharmacy in psychotic disorders: a critical review of neurobiology, efficacy, tolerability and cost effectiveness
van Bennekom, M. L., Gijsman, H. J., & Zitman, F. G. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113477709 · Cited by 82
Dose-dependent effects of antipsychotics on efficacy and adverse effects in schizophrenia
Yoshida, K., & Takeuchi, H. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.113098 · Cited by 84
Schizophrenia and type 2 diabetes mellitus
Mamakou, V., Thanopoulou, A. C., Gonidakis, F., Tentolouris, N., & Kontaxakis, V. P. (2018) · Psychiatriki · doi:10.22365/jpsych.2018.291.64 · Cited by 73
Trends in utilization and dosing of antipsychotic drugs in Scandinavia: Comparison of 2006 and 2016
Højlund, M., Pottegård, A., Johnsen, E., Kroken, R. A., Reutfors, J., Munk‐Jørgensen, P., & Correll, C. U. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13945 · Cited by 69
Off-Label Use of Atypical Antipsychotics
McKean, A., & Monasterio, E. (2012) · CNS Drugs · doi:10.2165/11632030-000000000-00000 · Cited by 67
A decision analysis of long‐term lithium treatment and the risk of renal failure
Werneke, U., Ott, M., Renberg, E. S., Taylor, D. M., & Stegmayr, B. G. (2012) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2012.01847.x · Cited by 66
Polypharmacy and Food–Drug Interactions Among Older Persons: A Review
Heuberger, R. (2012) · Journal of Nutrition in Gerontology and Geriatrics · doi:10.1080/21551197.2012.729902 · Cited by 57
Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats
Boyda, H. N., Procyshyn, R. M., Tse, L., Hawkes, E., Chen, J., Pang, C. C. Y., Honer, W. G., & Barr, A. M. (2012) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.110140 · Cited by 55
Retinal Changes in Schizophrenia: A Systematic Review and Meta-analysis Based on Individual Participant Data
Kazakos, C. T., & Karageorgiou, V. (2019) · Schizophrenia Bulletin · doi:10.1093/schbul/sbz106 · Cited by 53
Metabolic syndrome in psychiatrically hospitalized patients treated with antipsychotics and other psychotropics
Centorrino, F., Masters, G. A., Talamo, A., Baldessarini, R. J., & Öngür, D. (2012) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2257 · Cited by 55
A review of real-world data on the effects of aripiprazole on weight and metabolic outcomes in adults
Citrome, L., Kalsekar, I. D., Baker, R. A., & Hebden, T. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.908280 · Cited by 50
Association between second-generation antipsychotics and newly diagnosed treated diabetes mellitus: does the effect differ by dose?
Yood, M. U., DeLorenze, G. N., Quesenberry, C. P., Oliveria, S. A., Tsai, A., Kim, E., Cziraky, M. J., McQuade, R. D., Newcomer, J. W., & L'Italien, G. J. (2011) · BMC Psychiatry · doi:10.1186/1471-244x-11-197 · Cited by 50
Intermittent treatment with olanzapine causes sensitization of the metabolic side-effects in rats
Boyda, H. N., Procyshyn, R. M., Tse, L., Wong, D. W., Pang, C. C. Y., Honer, W. G., & Barr, A. M. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.02.019 · Cited by 48
Do antipsychotics increase diabetes risk in children and adolescents?
Galling, B., & Correll, C. U. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.979150 · Cited by 37
Prevalence of and factors associated with antipsychotic polypharmacy in patients with serious mental illness: Findings from a cross-sectional study in an upper-middle-income country
Armstrong, K. S., & Temmingh, H. S. (2017) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2016-2015 · Cited by 36
Clinical management of comorbid diabetes and psychotic disorders
Chwastiak, L., Freudenreich, O., Tek, C., McKibbin, C. L., Han, J., McCarron, R. M., & Wisse, B. E. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00105-4 · Cited by 36
Effect of Aripiprazole Lauroxil on Metabolic and Endocrine Profiles and Related Safety Considerations Among Patients With Acute Schizophrenia
Nasrallah, H. A., Newcomer, J. W., Risinger, R. C., Du, Y., Zummo, J., Bose, A., Stankovic, S., Silverman, B. L., & Ehrich, E. W. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.15m10467 · Cited by 34
Medication-induced hyperglycemia and diabetes mellitus: a review of current literature and practical management strategies
Jain, A. B., & Lai, V. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01628-0 · Cited by 32
A 52-Week, Double-Blind Evaluation of the Metabolic Effects of Aripiprazole and Lithium in Bipolar I Disorder
McIntyre, R. S., McElroy, S. L., Eudicone, J. M., Forbes, R. A., Carlson, B. X., & Baker, R. A. (2011) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.11m01182 · Cited by 32
Long-term safety and tolerability of aripiprazole lauroxil in patients with schizophrenia
Nasrallah, H. A., Aquila, R., Du, Y., Stanford, A. D., Claxton, A., & Weiden, P. J. (2018) · CNS Spectrums · doi:10.1017/s1092852918001104 · Cited by 29
Exercise Protects Against Olanzapine-Induced Hyperglycemia in Male C57BL/6J Mice
Castellani, L. N., Peppler, W. T., Miotto, P. M., Bush, N. D., & Wright, D. C. (2018) · Scientific Reports · doi:10.1038/s41598-018-19260-x · Cited by 28
AICAR Prevents Acute Olanzapine-Induced Disturbances in Glucose Homeostasis
Bush, N. D., Townsend, L. K., & Wright, D. C. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.248393 · Cited by 25
Systematic computerised cardiovascular health screening for people with severe mental illness
Yeomans, D., Dale, K., & Beedle, K. (2014) · Psychiatric Bulletin · doi:10.1192/pb.bp.113.045955 · Cited by 27
Role of aripiprazole in treatment-resistant schizophrenia
Mossaheb, N. (2012) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s13830 · Cited by 23
Differential Effects of Acute Treatment With Antipsychotic Drugs on Peripheral Catecholamines
Boyda, H. N., Ho, A. A., Tse, L., Procyshyn, R. M., Yuen, J. W. Y., Kim, D. D., Honer, W. G., & Barr, A. M. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.617428 · Cited by 22
Survival of bipolar depression, other type of depression and comorbid ailments: Ten-year longitudinal follow-up of 10,922 Taiwanese patients with depressive disorders (KCIS no. PSY1)
Chang, J., Chen, H.-H., Yen, A. M., Chen, S. L., & Lee, C. (2012) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.07.014 · Cited by 20
Prevalence and correlates of antipsychotic polypharmacy in Hong Kong
Lung, S. L. M., Lee, E. H. M., Chen, E. Y. H., Chan, K. W. S., Chang, W. C., & Hui, C. L. M. (2018) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2018.03.012 · Cited by 21
Pregnancy exposure to second-generation antipsychotics and the risk of gestational diabetes
Gentile, S. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.931368 · Cited by 21
Use of aripiprazole for delirium in the elderly: a short review
Kirino, E. (2014) · Psychogeriatrics · doi:10.1111/psyg.12088 · Cited by 20
Insight into mechanism of in vitro insulin secretion increase induced by antipsychotic clozapine: Role of FOXA1 and mitochondrial citrate carrier
Menga, A., Infantino, V., Iacobazzi, F., Convertini, P., Palmieri, F., & Iacobazzi, V. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.08.015 · Cited by 17
Leukocyte telomere length in Hispanic schizophrenia patients under treatment with olanzapine
Monroy‐Jaramillo, N., Rodríguez‐Agudelo, Y., Aviña-Cervantes, L. C., Roberts, D. L., Velligan, D. I., & Walss‐Bass, C. (2017) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2017.02.007 · Cited by 17
Bariatric Endocrinology: Principles of Medical Practice
González-Campoy, J. M., Richardson, B., Richardson, C., Gonzalez-Cameron, D., Ebrahim, A., Strobel, P., Martinez, T., Blaha, B., Ransom, M., Quinonez-Weislow, J., et al. (2014) · International Journal of Endocrinology · doi:10.1155/2014/917813 · Cited by 16
Mental healthcare staff's knowledge and experiences of diabetes care for persons with psychosis – a qualitative interview study
Hultsjö, S. (2012) · Primary Health Care Research & Development · doi:10.1017/s1463423612000321 · Cited by 16
Pharmacological management of diabetes in severe mental illness: a comprehensive clinical review of efficacy, safety and tolerability
Lally, J., Loughlin, A. O., Stubbs, B., Guérandel, A., O'Shea, D. B., & Gaughran, F. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1445968 · Cited by 18
Sex differences in the impact of diabetes on the risk of geriatric conditions
Lu, F., Chan, D., Kuo, H., & Wu, S. (2012) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/j.1447-0594.2012.00870.x · Cited by 16
Birth dimensions, severe mental illness and risk of type 2 diabetes in a cohort of Danish men born in 1953
Garriga, M., Wium‐Andersen, M. K., Wium‐Andersen, I. K., Nordentoft, M., & Osler, M. (2019) · European Psychiatry · doi:10.1016/j.eurpsy.2019.08.015 · Cited by 15
Psychiatric Disorders - Worldwide Advances
Uehara, T. (2011) · InTech eBooks · doi:10.5772/1289 · Cited by 16
Association between history of psychosis and cardiovascular disease in bipolar disorder
Prieto, M. L., McElroy, S. L., Hayes, S. N., Sutor, B., Kung, S., Bobo, W. V., Fuentes, M. E., Barboza, A. B. C., Crow, S. J., Ösby, U., et al. (2015) · Bipolar Disorders · doi:10.1111/bdi.12302 · Cited by 16
Brexpiprazole caused glycolipid metabolic disorder by inhibiting GLP1/GLP1R signaling in rats
Li, D., Yue, Q., Liu, L., Che, K., Liu, X., & Hu, C. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00680-x · Cited by 14
Comparative Safety of Antipsychotics: Another Look at the Risk of Diabetes
Moisan, J., Turgeon, M. C. D. M., Desjardins, O., & Grégoire, J. (2013) · The Canadian Journal of Psychiatry · doi:10.1177/070674371305800407 · Cited by 14
Patterns of clozapine and other antipsychotics prescriptions in patients with treatment-resistant schizophrenia in community mental health centers in São Paulo, Brazil
Silveira, A. S. D. A., Rocha, D. M. L. V., Attux, C. R. D. F., Daltio, C. S., da Silva, L. A., Elkis, H., Kane, J. M., & Bressan, R. A. (2015) · Archives of Clinical Psychiatry (São Paulo) · doi:10.1590/0101-60830000000069 · Cited by 14
Risk of New-Onset Diabetes After Long-Term Treatment With Clozapine in Comparison to Other Antipsychotics in Patients With Schizophrenia
Schulte, P. F. J., Bocxe, J. T. H., Doodeman, H. J., van Haelst, I. M. M., & Cohen, D. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000465 · Cited by 13
Assessing the risk of type 2 diabetes mellitus among children and adolescents with psychiatric disorders treated with atypical antipsychotics: a population-based nested case–control study
Lee, H., Song, D., Kwon, J., Han, E., Chang, M., & Kang, H.-Y. (2018) · European Child and Adolescent Psychiatry · doi:10.1007/s00787-018-1123-2 · Cited by 11
Schizophrenia, antipsychotic drugs and cardiovascular risk: Descriptive study in primary care
Sánchez, M. C., Escurriola, M. F., Bergé, D., Boreu, Q. F., Martin, M., & Goday, A. (2015) · European Psychiatry · doi:10.1016/j.eurpsy.2014.12.010 · Cited by 13
Antipsychotic polypharmacy: a needle in a haystack?
de Torre, A. L., Lertxundi, U., Hernández, R., & Medrano, J. (2012) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2012.01.019 · Cited by 14
Characteristics of Medicaid Recipients Receiving Persistent Antipsychotic Polypharmacy
Cotes, R. O., Goldsmith, D. R., Kopelovich, S. L., Lally, C. A., & Druss, B. G. (2017) · Community Mental Health Journal · doi:10.1007/s10597-017-0183-y · Cited by 14
Antipsychotic drugs and risk of newly diagnosed tuberculosis in schizophrenia
Liu, H., Hung, G. C., Yang, S., Liao, Y., Pan, C., Chen, C., & Kuo, C. (2018) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12736 · Cited by 13
Identifying determinants of diabetes risk and outcomes for people with severe mental illness: a mixed-methods study
Lister, J., Han, L., Bellass, S., Taylor, J., Alderson, S. L., Doran, T., Gilbody, S. M., Hewitt, C. E., Holt, R. I. G., Jacobs, R., et al. (2021) · Health Services and Delivery Research · doi:10.3310/hsdr09100 · Cited by 11
Psicosis, riesgo cardiovascular y mortalidad asociada: ¿vamos por el buen camino?
Sánchez, M. C., Escurriola, M. F., Bergé, D., Goday, A., & Callol, J. A. V. (2013) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2013.05.006 · Cited by 11
The association between birth weight, ponderal index, psychotropic medication, and type 2 diabetes in individuals with severe mental illness
Wium‐Andersen, M. K., Jørgensen, T. S. H., Jørgensen, M. B., Rungby, J., Hjorthøj, C. R., Sørensen, H. J., & Osler, M. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108181 · Cited by 11
Hyperosmolar Hyperglycemic State Associated With Ziprasidone Treatment
Létourneau, G., Abdel‐Baki, A., Dubreucq, S., Mahone, M., & Granger, B. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31822c96b7 · Cited by 11
Double jeopardy: diabetes and severe mental illness. Addressing the special needs of this vulnerable group
Blanchard, E., & Samaras, K. (2014) · Diabetes Management · doi:10.2217/dmt.14.24 · Cited by 10
The use of first and second-generation antipsychotic drugs and the potential to develop gestational diabetes mellitus among perinatal patients with psychosis
Kulkarni, J., Gurvich, C., Gilbert, H., Worsley, R., Li, Q., & Karimi, L. (2023) · Schizophrenia Research · doi:10.1016/j.schres.2023.01.030 · Cited by 10
Antipsychotics and the risk of diabetes and death among adults with serious mental illnesses
Poulos, J., Normand, S. T., Zelevinsky, K., Newcomer, J. W., Agniel, D. M., Abing, H. K., & Horvitz-Lennon, M. V. (2023) · Psychological Medicine · doi:10.1017/s0033291723001502 · Cited by 10
The type rather than the daily dose or number of antipsychotics affects the incidence of hyperglycemic progression
Ishikawa, S., Yamamura, R., Hashimoto, N., Okubo, R., Sawagashira, R., Ito, Y. M., Sato, N., & Kusumi, I. (2021) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2021.110453 · Cited by 10
Prediabetic increase in hemoglobin A1c compared with impaired fasting glucose in patients receiving antipsychotic drugs
Manu, P., Correll, C. U., Wampers, M., van Winkel, R., Yu, W., Mitchell, A. J., & Binder, M. D. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.05.002 · Cited by 10
Leveraging electronic health records to study pleiotropic effects on bipolar disorder and medical comorbidities
Prieto, M. L., Ryu, E., Jenkins, G. D., Batzler, A. J., Nassan, M. M., Barboza, A. B. C., Pathak, J., McElroy, S. L., Frye, M. A., & Biernacka, J. M. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.138 · Cited by 10
L0 Regularization for the Estimation of Piecewise Constant Hazard Rates in Survival Analysis
Bouaziz, O., & Nuel, G. (2017) · Applied Mathematics · doi:10.4236/am.2017.83031 · Cited by 9
Preventing and Treating Diabetes in Canadian Adults With Intellectual and Developmental Disabilities
Redquest, B. K., Ahmed, S., Balogh, R. S., & Lunsky, Y. (2019) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2019.05.016 · Cited by 9
Association of variants in SH2B1 and RABEP1 with worsening of low-density lipoprotein and glucose parameters in patients treated with psychotropic drugs
Delacrétaz, A., Zdralovic, A., Vandenberghe, F., Saigí-Morgui, N., Glatard, A., Quteineh, L., Gholam‐Rezaee, M., Raffoul, W., Applegate, L. A., Jafari, P., et al. (2017) · Gene · doi:10.1016/j.gene.2017.07.005 · Cited by 8
Psychopharmaka und Diabetes
Ress, C., Tschoner, A., Kaser, S., & Ebenbichler, C. F. (2011) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-011-0004-9 · Cited by 8
Misspecified poisson regression models for large‐scale registry data: inference for ‘largenand smallp’
Grøn, R., Gerds, T. A., & Andersen, P. K. (2015) · Statistics in Medicine · doi:10.1002/sim.6755 · Cited by 8
Self-citation
Schizophrenia and Related Psychoses
(2021) · Wiley eBooks · doi:10.1002/9781119870203.mpg001 · Cited by 9
The Choice of Either Quetiapine or Aripiprazole as Augmentation Treatment in a European Naturalistic Sample of Patients With Major Depressive Disorder
Bartova, L., Fugger, G., Dold, M., Kautzky, A., Swoboda, M. M. M., Rujescu, D., Zohar, J., Souery, D., Mendlewicz, J., Montgomery, S., et al. (2021) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab066 · Cited by 7
Antipsychotic Drug-Induced Increases in Peripheral Catecholamines are Associated With Glucose Intolerance
Boyda, H. N., Pham, M. M., Huang, J. Y., Ho, A. A., Procyshyn, R. M., Yuen, J. W. Y., Honer, W. G., & Barr, A. M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.765905 · Cited by 7
Fostering the use of clozapine in the severely mentally ill through academic detailing
Farhadian, S., Yee, M. V., & Christopher, M. L. D. (2011) · Mental Health Clinician · doi:10.9740/mhc.n87507 · Cited by 8
Post authorization safety study comparing quetiapine to risperidone and olanzapine
Heintjes, E. M., Overbeek, J. A., Beest, F. J. A. P., Brobert, G., & Herings, R. M. C. (2016) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2539 · Cited by 7
A Survey study of the Satisfaction and attitude of the Korean Psychiatrists toward Antipsychotic Polypharmacy
Chang, J., & Kim, B. (2014) · Annals of Clinical Psychiatry · doi:10.1177/104012371402600108 · Cited by 6
Risperidone-induced type 2 diabetes presenting with diabetic ketoacidosis
Fang, C. E. H., Rafey, M. F., Cunningham, Á., Dinneen, S. F., & Finucane, F. M. (2018) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-18-0031 · Cited by 7
Antipsychotic-Related Risks of Type 2 Diabetes Mellitus in Enrollees With Schizophrenia in the National Basic Public Health Service Program in Hunan Province, China
Ouyang, F., He, J., Cheng, X., Zhou, W., Xiao, S., & Fang, J. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.754775 · Cited by 7
Metabolic syndrome in a cohort of affectively ill patients, a naturalistic study
Vinberg, M., Madsen, M., Breum, L., Kessing, L. V., & Fink‐Jensen, A. (2011) · Nordic Journal of Psychiatry · doi:10.3109/08039488.2011.595821 · Cited by 6
Self-citation
The risk of diabetes and HbA1c deterioration during antipsychotic drug treatment: A Danish two‐cohort study among patients with first‐episode schizophrenia
Madsen, N. M., Sørensen, M. A., Danielsen, A. A., Højlund, M., Rohde, C., & Köhler‐Forsberg, O. (2024) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13760 · Cited by 5
Cardiometabolic Risk and Monitoring in Psychiatric Disorders
Samaras, K. (2016) · Springer eBooks · doi:10.1007/978-3-319-32480-7_18 · Cited by 5
Improving the physical health of overweight/obese people suffering from severe mental disorders: What is the role of antipsychotic drugs and of lifestyle psychosocial interventions?
Sampogna, G., Vincenzo, M. D., Luciano, M., Rocca, B. D., D’Ambrosio, E., Rampino, A., Amore, M., Calcagno, P., Rossi, A., Rossi, R., et al. (2024) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2024.11.029 · Cited by 5
Assessing effects of diet alteration on selected parameters of chronically mentally ill residents of a 24-hour Nursing Home. Part I: Effects of diet modification on carbohydrate-lipid metabolism
Friedrich, M. E., Fugiel, J., & Bruszkowska, M. (2020) · Psychiatria Polska · doi:10.12740/pp/123349 · Cited by 4
Revisiting diabetes risk of olanzapine versus aripiprazole in serious mental illness care
Agniel, D. M., Normand, S. T., Newcomer, J. W., Zelevinsky, K., Poulos, J., Tsuei, J., & Horvitz-Lennon, M. V. (2024) · BJPsych Open · doi:10.1192/bjo.2024.727 · Cited by 2
Assessing Effects of Diet Alteration on Carbohydrate–Lipid Metabolism of Antipsychotic-Treated Schizophrenia Patients in Interventional Study
Friedrich, M. E., Fugiel, J., & Sadowska, J. (2023) · Nutrients · doi:10.3390/nu15081871 · Cited by 3
Attention-deficit/hyperactivity disorder and cardiometabolic risk profile in patients with acute myocardial infarction: data from the SWEDEHEART registry
Yao, H., Brikell, I., Larsson, H., Li, L., Rietz, E. D., Hartman, C. A., Jernberg, T., Andell, P., & Chang, Z. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf151 · Cited by 4
Effets métaboliques indésirables des antipsychotiques
Fève, B. (2013) · Obésité · doi:10.1007/s11690-013-0365-x · Cited by 3

Authors: Kessing, L. V., Thomsen, A. F., Mogensen, U. B., & Andersen, P. K.
Affiliations: Copenhagen University Hospital (DK)
University of Copenhagen (DK)
Corresponding author: Kessing, Lars Vedel
ORCID: Kessing, Lars Vedel
Mogensen, Ulla Brasch
Andersen, Per Kragh
Venue: British Journal of Psychiatry
Publisher: Royal College of Psychiatrists
Published: 2010-10
Volume: 197
Issue: 4
Pages: 266-271
ISSN: 0007-1250 (ISSN-L)
1472-1465
DOI: 10.1192/bjp.bp.109.076935
OpenAlex: W2117234502
Cited by: 152
References: 26
Citations by year: 2026: 1 · 2025: 6 · 2024: 6 · 2023: 5 · 2022: 5 · 2021: 8 · 2020: 6 · 2019: 12 · 2018: 17 · 2017: 8 · 2016: 10 · 2015: 13 · 2014: 11 · 2013: 8 · 2012: 18
FWCI: 9.60
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.cambridge.org/core/terms (unspecified, 2650 d)
Locations: The British Journal of Psychiatry (publishedVersion)
PubMed (publishedVersion)
Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords: antipsychotic drugs, diabetes mellitus, new-onset diabetes, atypical antipsychotics, typical antipsychotics, olanzapine, risperidone, clozapine, ziprasidone, sertindole, amisulpride, quetiapine, aripiprazole, polypharmacy, treatment duration, drug safety
MeSH terms: Adult, Aged, Blood Glucose, Denmark, Diabetes Mellitus, Epidemiologic Methods, Female, Humans, Hypoglycemic Agents, Male, Middle Aged, Drug Prescriptions, Antipsychotic Agents, Sex Distribution, Pharmacoepidemiology, Polypharmacy, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Treatment with antipsychotics and the risk of diabetes in clinical practice

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks